cilostazol and Peripheral Arterial Diseases studies

Research Excerpts

Excerpt	Relevance	Reference
"This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease."	9.20	The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. ( Chen, CH; Chen, ST; Chern, CM; Chiou, HY; Chiu, HC; Hsu, CY; Hu, HH; Jeng, JS; Lee, JT; Lien, LM; Lin, HJ; Lin, RT; Liu, CH; Ma, H; Po, HL; Sun, MC; Sun, MH; Sun, Y, 2015)
"to assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study."	8.12	Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease. ( Giannoukas, A; Katsiki, N; Koufaki, P; Marakomichelakis, G; Papanas, N; Richter, D; Tentolouris, N, 2022)
"Although international guidelines recommend cilostazol as first-line therapy for peripheral arterial disease (PAD) because it improves the symptoms and quality of life, it remains an underused agent for amputation-free survival."	7.83	The use of cilostazol in patients with peripheral arterial disease: results of a national physician survey. ( de Donato, G; Galzerano, G; Mele, M; Ruzzi, U; Setacci, C; Setacci, F, 2016)
"Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication."	7.81	Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015)
"We analyzed 25 patients with demonstrated lower limb peripheral arterial disease to determine whether lipid peroxidation (LPO) or total antioxidant capacity (TAC) were modified after 6 months of cilostazol treatment (postintervention phase) with respect to the basal phase."	7.81	Cilostazol does not improve peripheral arterial disease-linked oxidative stress. ( Bernal-Lopez, MR; Gomez-Huelgas, R; Gomez-Martin, P; Peña, D; Tinahones, FJ, 2015)
"We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management."	7.80	Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. ( Harnan, S; Meng, Y; Michaels, J; O'Donnell, ME; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2014)
"Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients."	7.79	Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013)
"Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication."	6.47	Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? ( Corrado, E; Mikhailidis, DP; Patti, AM; Rini, GB; Rizzo, M, 2011)
"Renexin® is a combination pill of cilostazol and Ginkgo biloba leaf extract that is used for the improvement of ischemic symptoms associated with peripheral arterial disease (PAD)."	5.51	Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial. ( Ahn, SG; Ahn, TH; Chae, IH; Chang, K; Cho, DK; Cho, JM; Choi, D; Jin, HY; Kim, JH; Kim, JS; Kim, SH; Kim, SJ; Kim, SY; Kook, H; Kwon, K; Lee, HC; Lee, SR; Lim, SW; Park, CG; Yu, CW, 2022)
"In a lesion-based analysis, binary restenosis and reocclusion were significantly lower in the cilostazol group than in the non-cilostazol group (56."	5.38	Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. ( Hirano, K; Iida, O; Kawasaki, D; Soga, Y; Suzuki, K; Yamaoka, T, 2012)
"Cilostazol improves clinical endovascular therapy outcomes for femoropopliteal (FP) lesions in patients with symptomatic peripheral arterial disease, but whether it also has clinical benefits for patients after drug-eluting stent implantation remains unclear."	5.24	Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. ( Iida, O; Kawasaki, D; Matoba, S; Nanto, S; Soga, Y; Takahara, M; Yokoi, H; Zen, K, 2017)
"Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications."	5.22	Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. ( Manolis, AA; Manolis, AS; Manolis, TA; Melita, H; Mikhailidis, DP, 2022)
"This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease."	5.20	The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. ( Chen, CH; Chen, ST; Chern, CM; Chiou, HY; Chiu, HC; Hsu, CY; Hu, HH; Jeng, JS; Lee, JT; Lien, LM; Lin, HJ; Lin, RT; Liu, CH; Ma, H; Po, HL; Sun, MC; Sun, MH; Sun, Y, 2015)
"Our results showed that 200 mg cilostazol treatment decreased TACT duration in patients with peripheral artery disease, which may also prevent the development and/or recurrence of atrial fibrillation (AF)."	5.19	Cilostazol decreases total atrial conduction time in patients with peripheral artery disease. ( Açar, G; Akçakoyun, M; Alizade, E; Avcı, A; Bulut, M; Esen, AM; Güler, A; Kalkan, ME; Pala, S; Sahin, M; Simşek, Z, 2014)
"The effect of the prostaglandin I2 analog, beraprost sodium (BPS), on hemodialysis (HD) patients with peripheral arterial disease (PAD) has not been fully elucidated."	5.19	Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. ( Hidaka, S; Kobayashi, S; Kondoh, M; Miyaji, T; Moriya, H; Nakazawa, R; Ohtake, T; Sato, M, 2014)
"Continuous treatment of cilostazol in patients with HD with PAD significantly decreases the risk of ED visits, hemorrhagic stroke, and cardiovascular events and improves ED visit-free and cardiovascular event-free rates during long-term follow-up."	4.31	Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease. ( Chen, YY; Kao, ZK; Lin, CH; Wu, CK; Yang, YB; Yar, N, 2023)
"Cilostazol is a guideline-recommended drug that improves intermittent claudication and quality of life in patients with chronic atherosclerotic peripheral arterial disease."	4.31	Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol? ( Arslan, K; Can Depboylu, B; Funda Tetik, M; Harmandar, B; Ilhan, G; Istar, H; Yazman, S, 2023)
"Cilostazol is the only first-line medication for treating intermittent claudication, and the controlled-release (CR) formulation is associated with a lower prevalence of adverse events (AEs)."	4.31	Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease. ( Kim, JH; Lee, HJ; Shin, WY, 2023)
"to assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study."	4.12	Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease. ( Giannoukas, A; Katsiki, N; Koufaki, P; Marakomichelakis, G; Papanas, N; Richter, D; Tentolouris, N, 2022)
"The aim of this study was to evaluate the effect of a three-month cilostazol treatment on the health-related quality of life and on the lower-limb functional capacity in diabetic (DM) and non-diabetic patients (NDM) with intermittent claudication in the clinical practice."	3.96	Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients ( Farkas, K; Járai, Z; Kolossváry, E, 2020)
" The circulating SP-D level was affected by sex, diabetes mellitus, and cilostazol prescription."	3.88	Circulating Surfactant Protein-D Is Associated With Clinical Outcomes in Peripheral Artery Disease Patients Following Endovascular Therapy. ( Arimoto, T; Kubota, I; Miyamoto, T; Nishiyama, S; Otaki, Y; Shishido, T; Sugai, T; Takahashi, H; Watanabe, M; Watanabe, T; Yamanaka, T; Yokoyama, M, 2018)
"Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding."	3.88	Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. ( Alzamora, M; Forés, R; Giner-Soriano, M; Heras, A; Marsal, JR; Morros, R; Pera, G; Real, J; Ribes, E; Serna, MC, 2018)
"Cilostazol administration improves long-term clinical outcomes including prevention of MACE and stroke after endovascular therapy in HD patients with PAD."	3.83	Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease. ( Aoyama, T; Ishii, H; Ito, Y; Kamoi, D; Kumada, Y; Murohara, T; Sakakibara, T; Suzuki, S; Takahashi, H; Tanaka, A; Umemoto, N, 2016)
"Although international guidelines recommend cilostazol as first-line therapy for peripheral arterial disease (PAD) because it improves the symptoms and quality of life, it remains an underused agent for amputation-free survival."	3.83	The use of cilostazol in patients with peripheral arterial disease: results of a national physician survey. ( de Donato, G; Galzerano, G; Mele, M; Ruzzi, U; Setacci, C; Setacci, F, 2016)
"We analyzed 25 patients with demonstrated lower limb peripheral arterial disease to determine whether lipid peroxidation (LPO) or total antioxidant capacity (TAC) were modified after 6 months of cilostazol treatment (postintervention phase) with respect to the basal phase."	3.81	Cilostazol does not improve peripheral arterial disease-linked oxidative stress. ( Bernal-Lopez, MR; Gomez-Huelgas, R; Gomez-Martin, P; Peña, D; Tinahones, FJ, 2015)
"Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication."	3.81	Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015)
"Cilostazol increases the walking distance in patients with intermittent claudication, but there is scarce evidence of any effect on the risk for subsequent ischemic events, bleeding or death."	3.80	Cilostazol and outcome in outpatients with peripheral artery disease. ( Aguilar, E; Esteban, C; Jiménez Caballero, PE; Manzano, L; Monreal, M; Mujal, A; Perez, P; Sánchez Muñoz-Torrero, JF; Sauquillo, JC; Yeste, M, 2014)
"We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management."	3.80	Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. ( Harnan, S; Meng, Y; Michaels, J; O'Donnell, ME; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2014)
"Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients."	3.79	Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013)
" Sex-specific odds ratios of age, diabetes mellitus (DM), hypertension (HTN), coronary artery disease (CAD), cerebral vascular accident (CVA), or using cilostazol for LEA or PRP were explored."	3.77	Determinants of lower extremity amputation or revascularization procedure in patients with peripheral artery diseases: a population-based investigation. ( Chen, JJ; Lee, CH; Liau, CS; Lin, LY, 2011)
"Cilostazol has been reported to reduce intimal hyperplasia and subsequent repeat revascularization."	2.79	Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. ( Bae, JH; Baek, JY; Bong, JM; Cho, JH; Cho, YH; Choi, CU; Choi, HJ; Choi, SH; Choi, WG; Chung, WY; Her, SH; Kang, WY; Kim, EJ; Kim, JH; Kim, KC; Kim, MW; Kim, SM; Kim, WH; Kim, YH; Kim, YJ; Lee, SJ; Oh, DJ; Park, MW; Park, SH; Rha, SW; Seo, JB; Soh, JW; Suh, J, 2014)
"Cilostazol reduced angiographic restenosis after percutaneous transluminal angioplasty with provisional nitinol stenting for femoropopliteal lesions."	2.78	Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. ( Hamasaki, T; Hirano, K; Iida, O; Inoue, N; Isshiki, T; Kawasaki, D; Miyamoto, A; Miyashita, Y; Nakamura, M; Nanto, S; Shinozaki, N; Shintani, Y; Soga, Y; Suzuki, K; Tsuchiya, T; Urasawa, K; Yokoi, H; Yokoi, Y; Zen, K, 2013)
"Cilostazol treatment also increased freedom from target lesion revascularization (RR, 1."	2.72	Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization. ( Desai, K; Han, B; Kuziez, L; Yan, Y; Zayed, MA, 2021)
" Rivaroxaban of low dosage (2."	2.61	How To Assess a Claudication and When To Intervene. ( Armstrong, EJ; Hossain, P; Kokkinidis, DG, 2019)
"Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades."	2.52	Clinical efficacy and safety of cilostazol: a critical review of the literature. ( Finks, SW; Oliphant, CS; Rogers, KC, 2015)
"In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb."	2.50	Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014)
" From a clinical point of view, Cilostazol is indicated in stage IIb of PAOD (Fontaine); its recommended dosage is 2x100 (reduced in case of moderate side effects, 2x50) mg with detectable prolongation of subjective (reported by the patient) and objective walking distance (but not in smokers [!]; ABI-based measurement of the effect not suitable) and partially with an improval of the quality of life (associated with a prolonged but steadily improving therapeutic effect from the 4th to the 6th week until the 6th to the 12th month)."	2.48	[Role of cilostazol in the sequential therapeutic spectrum of the peripheral arterial occlusion disease (PAOD)]. ( Halloul, Z; Meyer, F; Weber, M; Weber, T, 2012)
"Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication."	2.47	Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? ( Corrado, E; Mikhailidis, DP; Patti, AM; Rini, GB; Rizzo, M, 2011)
"Cilostazol use was associated with early expansive graft remodeling."	1.56	Heterogeneous and dynamic lumen remodeling of the entire infrainguinal vein bypass grafts in patients. ( Berceli, SA; DeSart, K; He, Y; Irwin, A; Kubilis, PS; Nelson, PR; Tran-Son-Tay, R, 2020)
"Cilostazol treatment was inversely associated with restenosis for the first 2 years following EVT (P < ."	1.42	Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease. ( Hirano, K; Iida, O; Kawasaki, D; Nanto, K; Shintani, Y; Soga, Y; Suematsu, N; Suzuki, K; Takahara, M; Uematsu, M; Yamaoka, T, 2015)
"Cilostazol was not associated with an increase in any arrhythmic complication."	1.39	Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes. ( Bauer-Mehren, A; Iyer, SV; Leeper, NJ; Lependu, P; Olson, C; Shah, NH, 2013)
"In a lesion-based analysis, binary restenosis and reocclusion were significantly lower in the cilostazol group than in the non-cilostazol group (56."	1.38	Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. ( Hirano, K; Iida, O; Kawasaki, D; Soga, Y; Suzuki, K; Yamaoka, T, 2012)
"Primary endpoint was binary restenosis rate."	1.38	Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. ( Hirano, K; Iida, O; Nobuyoshi, M; Soga, Y; Suzuki, K; Yokoi, H, 2012)

Research

Studies (75)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Change From Baseline in Claudication Onset Time at Day 180

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (1.33)	29.6817
2010's	58 (77.33)	24.3611
2020's	16 (21.33)	2.80

Authors	Studies
Manolis, AA	1
Manolis, TA	1
Melita, H	1
Mikhailidis, DP	3
Manolis, AS	1
Kook, H	2
Yu, CW	2
Choi, D	1
Ahn, TH	1
Chang, K	1
Cho, JM	1
Kim, SJ	1
Park, CG	1
Cho, DK	1
Kim, SH	1
Lee, HC	1
Jin, HY	1
Chae, IH	2
Kwon, K	1
Ahn, SG	1
Kim, JH	4
Lee, SR	2
Kim, JS	1
Kim, SY	1
Lim, SW	1
Lauters, R	1
Wilkin, D	1
Miura, T	2
Miyashita, Y	4
Hozawa, K	2
Doijiri, T	2
Kato, T	1
Hayakawa, N	1
Hashizume, N	1
Nakano, M	1
Ikeda, U	2
Kuwahara, K	2
Wu, CK	1
Lin, CH	1
Yar, N	1
Kao, ZK	1
Yang, YB	1
Chen, YY	1
Katsiki, N	1
Tentolouris, N	1
Marakomichelakis, G	1
Richter, D	1
Giannoukas, A	1
Koufaki, P	1
Papanas, N	1
Can Depboylu, B	1
Yazman, S	1
Harmandar, B	1
Funda Tetik, M	1
Istar, H	1
Arslan, K	1
Ilhan, G	1
Cha, JJ	1
Cho, JY	1
Lim, S	1
Joo, HJ	1
Park, JH	1
Hong, SJ	1
Lim, DS	1
Lee, SH	1
Ko, YG	1
Min, PK	1
Lee, JH	1
Yoon, CH	1
Lee, SW	1
Choi, SH	2
Koh, YS	1
Shin, WY	1
Lee, HJ	1
He, Y	1
DeSart, K	1
Kubilis, PS	1
Irwin, A	1
Tran-Son-Tay, R	1
Nelson, PR	1
Berceli, SA	1
Hossain, P	1
Kokkinidis, DG	1
Armstrong, EJ	1
Bartholomew, J	1
Bishop, GJ	1
Mohammed, M	1
Gosch, K	1
Safley, D	1
Jelani, QU	1
Aronow, HD	1
Mena, C	1
Shishehbor, MH	2
Spertus, JA	1
Abbott, JD	1
Smolderen, KG	1
Colak, B	1
Orhan, A	1
Ece, I	1
Yormaz, S	1
Yilmaz, H	1
Sahin, M	2
Desai, K	1
Han, B	1
Kuziez, L	1
Yan, Y	1
Zayed, MA	1
Farkas, K	1
Kolossváry, E	1
Járai, Z	1
Burleva, EP	1
Korelin, SV	1
Soga, Y	10
Takahara, M	3
Iida, O	9
Yamauchi, Y	1
Hirano, K	6
Fukunaga, M	1
Zen, K	4
Suzuki, K	7
Shintani, Y	3
Tsuchiya, T	2
Yamaoka, T	3
Ando, K	2
Tomoi, Y	1
Fujihara, M	1
Wang, Z	1
Liu, T	1
Chen, X	1
You, H	1
Zhang, Q	1
Xue, J	1
Zheng, Y	1
Luo, D	1
Hernandez-Suarez, DF	1
Núñez-Medina, H	1
Scott, SA	1
Lopez-Candales, A	1
Wiley, JM	1
Garcia, MJ	1
Melin, K	1
Nieves-Borrero, K	1
Rodriguez-Ruiz, C	1
Marshall, L	1
Duconge, J	1
Hamasaki, T	2
Edahiro, R	1
Inoue, N	3
Yokoi, Y	2
Kawasaki, D	5
Urasawa, K	2
Aodo, K	1
Real, J	1
Serna, MC	1
Giner-Soriano, M	1
Forés, R	1
Pera, G	1
Ribes, E	1
Alzamora, M	1
Marsal, JR	1
Heras, A	1
Morros, R	1
Otaki, Y	1
Watanabe, T	1
Takahashi, H	2
Sugai, T	1
Yokoyama, M	1
Nishiyama, S	1
Arimoto, T	1
Shishido, T	1
Miyamoto, T	1
Yamanaka, T	1
Kubota, I	1
Watanabe, M	1
Furuyama, T	1
Onohara, T	1
Yamashita, S	1
Yoshiga, R	1
Yoshiya, K	1
Inoue, K	1
Morisaki, K	1
Kyuragi, R	2
Matsumoto, T	1
Maehara, Y	1
Kan, CD	1
Wang, JN	1
Li, WP	1
Lin, SH	1
Chen, WL	1
Hsu, YP	1
Yeh, CS	1
Megaly, M	1
Abraham, B	1
Saad, M	1
Mekaiel, A	1
Soukas, P	1
Banerjee, S	1
Ichihashi, S	1
Shibata, T	1
Fujimura, N	1
Nagatomi, S	1
Yamamoto, H	1
Adachi, A	1
Iwakoshi, S	1
Bolstad, F	1
Saeki, K	1
Obayashi, K	1
Kichikawa, K	1
Lee, WH	1
Chu, CY	1
Hsu, PC	1
Su, HM	1
Lin, TH	1
Voon, WC	1
Lai, WT	1
Sheu, SH	1
Watson, A	1
Stansby, G	3
Zeller, T	1
Trenk, D	1
Yokoi, H	4
Miyamoto, A	1
Shinozaki, N	1
Nakamura, M	2
Isshiki, T	1
Nanto, S	3
Leeper, NJ	1
Bauer-Mehren, A	1
Iyer, SV	1
Lependu, P	1
Olson, C	1
Shah, NH	1
Sobieszczyk, P	1
Eisenhauer, A	1
Alizade, E	1
Simşek, Z	1
Açar, G	1
Bulut, M	1
Güler, A	1
Avcı, A	1
Kalkan, ME	1
Pala, S	1
Akçakoyun, M	1
Esen, AM	1
Chao, TH	1
Tseng, SY	1
Chen, IC	1
Tsai, YS	1
Huang, YY	1
Liu, PY	1
Ou, HY	1
Li, YH	1
Wu, HL	1
Cho, CL	1
Tsai, LM	1
Chen, JH	1
Ohtake, T	1
Sato, M	1
Nakazawa, R	1
Kondoh, M	1
Miyaji, T	1
Moriya, H	1
Hidaka, S	1
Kobayashi, S	1
Resnick, KA	1
Gordon, IL	1
Spiliopoulos, S	1
Perez, P	1
Esteban, C	1
Sauquillo, JC	1
Yeste, M	1
Manzano, L	1
Mujal, A	1
Jiménez Caballero, PE	1
Aguilar, E	1
Sánchez Muñoz-Torrero, JF	1
Monreal, M	1
Di Minno, G	1
Spadarella, G	1
Cafaro, G	1
Petitto, M	1
Lupoli, R	1
Di Minno, A	1
de Gaetano, G	1
Tremoli, E	1
Azarbal, A	1
Clavijo, L	1
Gaglia, MA	1
Park, SH	1
Rha, SW	1
Choi, CU	1
Kim, EJ	1
Oh, DJ	1
Cho, YH	1
Choi, WG	1
Lee, SJ	1
Kim, YH	1
Kim, WH	1
Kim, KC	1
Cho, JH	1
Kim, SM	1
Bae, JH	1
Bong, JM	1
Kang, WY	1
Baek, JY	1
Seo, JB	1
Chung, WY	1
Park, MW	1
Her, SH	1
Suh, J	1
Kim, MW	1
Kim, YJ	1
Choi, HJ	1
Soh, JW	1
Nanto, K	1
Suematsu, N	1
Uematsu, M	2
Bernal-Lopez, MR	1
Peña, D	1
Gomez-Martin, P	1
Tinahones, FJ	1
Gomez-Huelgas, R	1
Jeng, JS	1
Sun, Y	1
Lee, JT	1
Lin, RT	1
Chen, CH	1
Po, HL	1
Lin, HJ	1
Liu, CH	1
Sun, MH	1
Sun, MC	1
Chern, CM	1
Lien, LM	1
Chiu, HC	1
Hu, HH	1
Chiou, HY	1
Chen, ST	1
Ma, H	1
Hsu, CY	1
Agrawal, K	1
Eberhardt, RT	1
Neel, JD	1
Kruse, RL	1
Dombrovskiy, VY	1
Vogel, TR	1
Rybak, Z	1
Rogers, KC	1
Oliphant, CS	1
Finks, SW	1
Ishii, H	1
Aoyama, T	1
Kumada, Y	1
Kamoi, D	1
Sakakibara, T	1
Umemoto, N	1
Suzuki, S	1
Tanaka, A	1
Ito, Y	1
Murohara, T	1
Shiga, T	1
Sahara, H	1
Orito, K	1
Iftikhar, O	1
Oliveros, K	1
Tafur, AJ	1
Casanegra, AI	1
de Donato, G	2
Setacci, F	2
Galzerano, G	2
Mele, M	2
Ruzzi, U	1
Setacci, C	2
Cimminiello, C	1
Polo Friz, H	1
Marano, G	1
Arpaia, G	1
Boracchi, P	1
Spezzigu, G	1
Visonà, A	1
Matoba, S	1
McDermott, MM	1
Kibbe, MR	1
Giannace, G	1
Schirmang, TC	1
Ahn, SH	1
Murphy, TP	1
Dubel, GJ	1
Soares, GM	1
Chen, JJ	1
Lee, CH	1
Lin, LY	1
Liau, CS	1
Rhee, SY	1
Kim, YS	1
Chon, S	1
Oh, S	1
Woo, JT	1
Kim, SW	1
Kim, JW	1
Rizzo, M	1
Corrado, E	1
Patti, AM	1
Rini, GB	1
Muramatsu, T	1
Nobuyoshi, M	2
Meguro, T	1
Brass, EP	1
Cooper, LT	1
Morgan, RE	1
Hiatt, WR	2
Squires, H	2
Simpson, E	2
Meng, Y	2
Harnan, S	2
Stevens, J	1
Wong, R	1
Thomas, S	2
Michaels, J	2
Ansel, GM	1
Weber, T	1
Meyer, F	1
Weber, M	1
Halloul, Z	1
Garimella, PS	1
Hart, PD	1
O'Hare, A	1
DeLoach, S	1
Herzog, CA	1
Hirsch, AT	1
Goldenberg, NA	1
Krantz, MJ	1
Stevens, JW	1
O'Donnell, ME	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group and Phase III Clinical Trial to Evaluate in Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease[NCT03318276]	Phase 3	170 participants (Actual)	Interventional	2017-02-20	Completed
Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment[NCT00912756]	Phase 4	200 participants (Anticipated)	Interventional	2009-03-31	Recruiting
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease[NCT02174939]	Phase 4	300 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells Mediated Through Multiple Mechanisms in Patients With High Risk for Cardiovascular Disease[NCT02194686]	Phase 4	71 participants (Actual)	Interventional	2013-01-31	Completed
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]	Phase 4	826 participants (Actual)	Interventional	2016-11-30	Completed
Efficacy of Self-Expanding Nitinol S.M.A.R.T-CONTROL Stent Versus Complete SE Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP Trial)[NCT01570803]		0 participants (Actual)	Interventional	2013-01-31	Withdrawn (stopped due to Study could not be initiated due to lack of research funding from the sponsors.)
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969]	Phase 4	2,200 participants (Actual)	Interventional	2016-04-30	Completed
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172]	Phase 4	164 participants (Actual)	Interventional	2008-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

Change From Baseline in Claudication Onset Time at Day 90

Intervention	Log Minutes (Mean)
Cilostazol + L-Carnitine	1.065
Cilostazol + Placebo	0.896

Change From Baseline in Peak Walking Time (PWT) at Day 180

Intervention	Log Minutes (Mean)
Cilostazol + L-Carnitine	1.001
Cilostazol + Placebo	0.815

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

Change From Baseline in Peak Walking Time at Day 180

Intervention	Log Minutes (Mean)
Cilostazol + L-Carnitine	0.241
Cilostazol + Placebo	0.134

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

Change From Baseline in Peak Walking Time at Day 90

Intervention	Log Minutes (Mean)
Cilostazol + L-Carnitine	0.267
Cilostazol + Placebo	0.145

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180

Intervention	Log Minutes (Mean)
Cilostazol + L-Carnitine	0.166
Cilostazol + Placebo	0.139

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90

Article	Year
Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. Journal of clinical pharmacology, 2022, Volume: 62, Issue:3 Topics: Animals; Cilostazol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination;	2022
How To Assess a Claudication and When To Intervene. Current cardiology reports, 2019, 11-14, Volume: 21, Issue:12 Topics: Angiotensin-Converting Enzyme Inhibitors; Ankle Brachial Index; Cilostazol; Humans; Intermittent Cla	2019
Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization. Journal of vascular surgery, 2021, Volume: 73, Issue:2 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Critical Illness; Endovascular Procedures	2021
[Prospects of clinical application of cilostazol for peripheral artery disease]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2020, Volume: 26, Issue:3 Topics: Cilostazol; Humans; Intermittent Claudication; Peripheral Arterial Disease; Russia; Tetrazoles	2020
Outcomes with cilostazol after endovascular therapy of peripheral artery disease. Vascular medicine (London, England), 2019, Volume: 24, Issue:4 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Endovascular Proce	2019
Management of patients after endovascular interventions for peripheral artery disease. Circulation, 2013, Aug-13, Volume: 128, Issue:7 Topics: Aftercare; Angioplasty, Balloon; Ankle Brachial Index; Aspirin; Cilostazol; Clinical Trials as Topic	2013
Antiplatelet therapy in critical limb ischemia: update on clopidogrel and cilostazol. The Journal of cardiovascular surgery, 2014, Volume: 55, Issue:5 Topics: Cilostazol; Clopidogrel; Combined Modality Therapy; Critical Illness; Drug Therapy, Combination; End	2014
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Annals of medicine, 2014, Volume: 46, Issue:7 Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int	2014
Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data? Journal of cardiovascular pharmacology and therapeutics, 2015, Volume: 20, Issue:2 Topics: Aspirin; Cilostazol; Dipyridamole; Endovascular Procedures; Extremities; Humans; Ischemia; Periphera	2015
Contemporary medical management of peripheral arterial disease: a focus on risk reduction and symptom relief for intermittent claudication. Cardiology clinics, 2015, Volume: 33, Issue:1 Topics: Ankle Brachial Index; Cilostazol; Combined Modality Therapy; Exercise Therapy; Humans; Intermittent	2015
Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs, 2015, Volume: 75, Issue:4 Topics: Animals; Cilostazol; Hemorrhage; Humans; Intermittent Claudication; Peripheral Arterial Disease; Pla	2015
Prevention of Femoropopliteal In-Stent Restenosis With Cilostazol: A Meta-Analysis. Angiology, 2016, Volume: 67, Issue:6 Topics: Cardiovascular Agents; Cilostazol; Endovascular Procedures; Femoral Artery; Humans; Odds Ratio; Peri	2016
Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol. Annals of vascular surgery, 2017, Volume: 41 Topics: Cardiovascular Agents; Cilostazol; Coronary Artery Disease; Coronary Restenosis; Endovascular Proced	2017
Peripheral arterial disease: update of overview and treatment. Medicine and health, Rhode Island, 2009, Volume: 92, Issue:12 Topics: Aged; Ankle Brachial Index; Cilostazol; Exercise Therapy; Female; Humans; Magnetic Resonance Angiogr	2009
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4 Topics: Atherosclerosis; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Diabetes Mellitus, Type 2	2011
A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:40 Topics: Cilostazol; Cost-Benefit Analysis; Humans; Intermittent Claudication; Nafronyl; Nicotinic Acids; Pen	2011
[Role of cilostazol in the sequential therapeutic spectrum of the peripheral arterial occlusion disease (PAOD)]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:20 Topics: Arterial Occlusive Diseases; Cilostazol; Dose-Response Relationship, Drug; Germany; Humans; Peripher	2012
Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2012, Volume: 60, Issue:4 Topics: Amputation, Surgical; Ankle Brachial Index; Atherosclerosis; Cilostazol; Diabetic Foot; Exercise The	2012

Article	Year
Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial. Clinical therapeutics, 2022, Volume: 44, Issue:4 Topics: Cilostazol; Double-Blind Method; Humans; Pain; Peripheral Arterial Disease; Plant Extracts; Treatmen	2022
Cilostazol effectiveness in reducing drug-coated stent restenosis in the superficial femoral artery: The ZERO study. PloS one, 2022, Volume: 17, Issue:7 Topics: Cilostazol; Constriction, Pathologic; Drug-Eluting Stents; Femoral Artery; Humans; Peripheral Arteri	2022
Efficacy of CilostAzol for Below-the-Knee Artery Disease after Balloon AnGioplasty in PatiEnts with Severe Limb Ischemia (CABBAGE Trial). Annals of vascular surgery, 2017, Volume: 45 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Angioplasty, Balloon; Cardiovascular Age	2017
Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug metabolism and personalized therapy, 2018, 03-28, Volume: 33, Issue:1 Topics: Aged; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; Blood Platelets; Cilost	2018
Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2018, Volume: 25, Issue:3 Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Cilostazol; Female; Femoral Ar	2018
Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery. Circulation. Cardiovascular interventions, 2018, Volume: 11, Issue:8 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Double-Blind Metho	2018
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation, 2013, Jun-11, Volume: 127, Issue:23 Topics: Aged; Aged, 80 and over; Alloys; Angioplasty; Aspirin; Cardiovascular Diseases; Cilostazol; Constric	2013
Cilostazol decreases total atrial conduction time in patients with peripheral artery disease. Perfusion, 2014, Volume: 29, Issue:3 Topics: Aged; Atrial Fibrillation; Cilostazol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Periphe	2014
Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease. International journal of cardiology, 2014, Mar-15, Volume: 172, Issue:2 Topics: Biomarkers; Cell Movement; Cell Proliferation; Cilostazol; Collateral Circulation; Double-Blind Meth	2014
Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease. International journal of cardiology, 2014, Mar-15, Volume: 172, Issue:2 Topics: Biomarkers; Cell Movement; Cell Proliferation; Cilostazol; Collateral Circulation; Double-Blind Meth	2014
Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease. International journal of cardiology, 2014, Mar-15, Volume: 172, Issue:2 Topics: Biomarkers; Cell Movement; Cell Proliferation; Cilostazol; Collateral Circulation; Double-Blind Meth	2014
Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease. International journal of cardiology, 2014, Mar-15, Volume: 172, Issue:2 Topics: Biomarkers; Cell Movement; Cell Proliferation; Cilostazol; Collateral Circulation; Double-Blind Meth	2014
Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2014, Volume: 18, Issue:1 Topics: Aged; Aged, 80 and over; Cilostazol; Epoprostenol; Female; Heart Rate; Humans; Male; Microcirculatio	2014
Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. Trials, 2014, Sep-10, Volume: 15 Topics: Alloys; Angioplasty, Balloon; Aspirin; Cilostazol; Clinical Protocols; Clopidogrel; Drug Therapy, Co	2014
The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:1 Topics: Aspirin; Cilostazol; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hu	2015
Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. Journal of vascular surgery, 2017, Volume: 65, Issue:3 Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting S	2017
Long-term results of the S.M.A.R.T. Control(TM) stent for superficial femoral artery lesions, J-SMART registry. Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:4 Topics: Age Factors; Aged; Aged, 80 and over; Cilostazol; Female; Femoral Artery; Follow-Up Studies; Graft O	2011
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of vascular surgery, 2012, Volume: 55, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Cilostazol; Dose-Resp	2012
L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vascular medicine (London, England), 2012, Volume: 17, Issue:3 Topics: Adult; Aged; Carnitine; Cilostazol; Double-Blind Method; Drug Therapy, Combination; Exercise Test; F	2012

Article	Year
Cilostazol for Intermittent Claudication Caused by Peripheral Artery Disease. American family physician, 2022, 04-01, Volume: 105, Issue:4 Topics: Cilostazol; Humans; Intermittent Claudication; Peripheral Arterial Disease; Tetrazoles; Vasodilator	2022
Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease. Journal of atherosclerosis and thrombosis, 2023, Aug-01, Volume: 30, Issue:8 Topics: Adult; Cilostazol; Hemorrhagic Stroke; Humans; Ischemic Stroke; Peripheral Arterial Disease; Platele	2023
Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease. BMC research notes, 2022, Dec-20, Volume: 15, Issue:1 Topics: Aged; Cilostazol; Female; Humans; Intermittent Claudication; Male; Middle Aged; Pain; Peripheral Art	2022
Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol? Texas Heart Institute journal, 2023, 01-01, Volume: 50, Issue:1 Topics: Atherosclerosis; Cilostazol; Diabetic Angiopathies; Humans; Peripheral Arterial Disease; Quality of	2023
Effect of Cilostazol on Patients With Diabetes Who Underwent Endovascular Treatment for Peripheral Artery Disease. Journal of the American Heart Association, 2023, 06-20, Volume: 12, Issue:12 Topics: Cilostazol; Diabetes Mellitus; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors;	2023
Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease. Clinical drug investigation, 2023, Volume: 43, Issue:9 Topics: Cilostazol; Coronary Artery Disease; Delayed-Action Preparations; Drug-Related Side Effects and Adve	2023
Heterogeneous and dynamic lumen remodeling of the entire infrainguinal vein bypass grafts in patients. Journal of vascular surgery, 2020, Volume: 71, Issue:5 Topics: Aged; Cardiovascular Agents; Cilostazol; Computed Tomography Angiography; Female; Humans; Longitudin	2020
New treatments for peripheral artery disease. Cleveland Clinic journal of medicine, 2020, Volume: 87, Issue:5 suppl 1 Topics: Ankle Brachial Index; Anticholesteremic Agents; Cilostazol; Diet, Healthy; Dual Anti-Platelet Therap	2020
Cilostazol and peripheral artery disease-specific health status in ambulatory patients with symptomatic PAD. International journal of cardiology, 2020, 10-01, Volume: 316 Topics: Aged; Cilostazol; Female; Health Status; Humans; Intermittent Claudication; Male; Middle Aged; Perip	2020
Comparison of the effects of cilostazol and aspirin on wound healing in patients with diabetic foot ulcer and peripheral artery disease. Annali italiani di chirurgia, 2020, Volume: 91 Topics: Aspirin; Cilostazol; Diabetes Mellitus; Diabetic Foot; Humans; Peripheral Arterial Disease; Retrospe	2020
Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients Orvosi hetilap, 2020, Volume: 161, Issue:38 Topics: Aged; Case-Control Studies; Cilostazol; Diabetes Complications; Diabetes Mellitus; Female; Humans; I	2020
Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2017, Volume: 24, Issue:5 Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cilostazol; Databases, Factual; Endovascular Procedu	2017
Low molecular weight fucoidan ameliorates hindlimb ischemic injury in type 2 diabetic rats. Journal of ethnopharmacology, 2018, Jan-10, Volume: 210 Topics: Animals; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relat	2018
Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. BMC cardiovascular disorders, 2018, 05-08, Volume: 18, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Agents; Cerebrovascular Disorders; Cilostazol;	2018
Circulating Surfactant Protein-D Is Associated With Clinical Outcomes in Peripheral Artery Disease Patients Following Endovascular Therapy. Circulation journal : official journal of the Japanese Circulation Society, 2018, 06-25, Volume: 82, Issue:7 Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cilostazol; Diabetes Mellitus; Endovascular Proced	2018
Prognostic factors of ulcer healing and amputation-free survival in patients with critical limb ischemia. Vascular, 2018, Volume: 26, Issue:6 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Critical Illness; Debridement; Disease-Fr	2018
Clinical ultrasound stimulating angiogenesis following drug-release from polymersomes on the ischemic zone for peripheral arterial occlusive disease. Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:7 Topics: Angiogenesis Inducing Agents; Animals; Arterial Occlusive Diseases; Bronchodilator Agents; Cilostazo	2018
Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2019, Volume: 26, Issue:5 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Constriction, Path	2019
Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. Thrombosis research, 2013, Volume: 132, Issue:2 Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Cohort Studies; Female; Humans; Longitudinal Studies; Male;	2013
Cilostazol for peripheral arterial disease could reduce stroke risk? Thrombosis research, 2013, Volume: 132, Issue:2 Topics: Cilostazol; Female; Humans; Male; Peripheral Arterial Disease; Stroke; Tetrazoles; Vasodilator Agent	2013
Cilostazol: the "poor man's" replacement of drug-eluting stents and balloons? Circulation, 2013, Jun-11, Volume: 127, Issue:23 Topics: Angioplasty; Cilostazol; Female; Humans; Male; Peripheral Arterial Disease; Platelet Aggregation Inh	2013
Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes. PloS one, 2013, Volume: 8, Issue:5 Topics: Aged; Aged, 80 and over; Cilostazol; Cohort Studies; Data Mining; Female; Heart Failure; Humans; Mal	2013
Effects of cilostazol on arterial wound healing: a retrospective analysis. Annals of vascular surgery, 2014, Volume: 28, Issue:6 Topics: Aged; Cilostazol; Drug Administration Schedule; Female; Humans; Leg Ulcer; Limb Salvage; Lower Extre	2014
Peripheral artery disease. Heart health for your legs. Mayo Clinic health letter (English ed.), 2014, Volume: 32, Issue:3 Topics: Angioplasty, Balloon; Atherosclerosis; Cilostazol; Diabetes Complications; Exercise; Fibrinolytic Ag	2014
Cilostazol and outcome in outpatients with peripheral artery disease. Thrombosis research, 2014, Volume: 134, Issue:2 Topics: Aged; Cilostazol; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intermittent Claudication; Male;	2014
Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease. Angiology, 2015, Volume: 66, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Alloys; Cardiovascular Agents; Cilostazol; Databases,	2015
Cilostazol does not improve peripheral arterial disease-linked oxidative stress. Cardiovascular therapeutics, 2015, Volume: 33, Issue:1 Topics: Aged; Antioxidants; Cilostazol; Female; Humans; Lipid Peroxidation; Male; Middle Aged; Oxidative Str	2015
Cilostazol and freedom from amputation after lower extremity revascularization. Journal of vascular surgery, 2015, Volume: 61, Issue:4 Topics: Aged; Aged, 80 and over; Amputation, Surgical; Chi-Square Distribution; Cilostazol; Comorbidity; Dis	2015
Effectiveness of cilostazol in the treatment of peripheral arterial obstruction. Polskie Archiwum Medycyny Wewnetrznej, 2015, Volume: 125, Issue:3 Topics: Cilostazol; Fibrinolytic Agents; Humans; Oxidative Stress; Peripheral Arterial Disease; Tetrazoles;	2015
Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease. Journal of cardiology, 2016, Volume: 67, Issue:2 Topics: Aged; Cilostazol; Disease-Free Survival; Female; Humans; Kidney Diseases; Male; Middle Aged; Periphe	2016
Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. Pharmacology, 2015, Volume: 96, Issue:5-6 Topics: Angiogenic Proteins; Animals; Carnitine; Cilostazol; Disease Models, Animal; Drug Therapy, Combinati	2015
The use of cilostazol in patients with peripheral arterial disease: results of a national physician survey. The Journal of cardiovascular surgery, 2016, Volume: 57, Issue:3 Topics: Cilostazol; Cross-Sectional Studies; Female; Humans; Italy; Male; Patient Selection; Peripheral Arte	2016
Patterns and determinants of use of pharmacological therapies for intermittent claudication in PAD outpatients: results of the IDOMENEO study. International angiology : a journal of the International Union of Angiology, 2017, Volume: 36, Issue:3 Topics: Aged; Ankle Brachial Index; Cilostazol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito	2017
Improving Lower Extremity Functioning in Peripheral Artery Disease: Exercise, Endovascular Revascularization, or Both? JAMA, 2017, 02-21, Volume: 317, Issue:7 Topics: Adult; Cilostazol; Combined Modality Therapy; Endovascular Procedures; Exercise Test; Exercise Thera	2017
Determinants of lower extremity amputation or revascularization procedure in patients with peripheral artery diseases: a population-based investigation. Angiology, 2011, Volume: 62, Issue:4 Topics: Aged; Amputation, Surgical; Cilostazol; Coronary Artery Disease; Female; Humans; Hypertension; Logis	2011
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus. Diabetes research and clinical practice, 2011, Volume: 91, Issue:1 Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty	2011
The door is open and the next step is forthcoming--lesson from J-SMART registry. Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:4 Topics: Age Factors; Aged; Aged, 80 and over; Cilostazol; Female; Femoral Artery; Follow-Up Studies; Graft O	2011
Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Mar-01, Volume: 79, Issue:4 Topics: Aged; Aged, 80 and over; Alloys; Angioplasty; Chi-Square Distribution; Cilostazol; Constriction, Pat	2012
Improved antiplatelet therapy? There's a generic thought. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Mar-01, Volume: 79, Issue:4 Topics: Angioplasty; Cilostazol; Female; Femoral Artery; Humans; Male; Peripheral Arterial Disease; Platelet	2012
Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2012, Volume: 44, Issue:6 Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Cilos	2012
Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology, 2014, Volume: 65, Issue:3 Topics: Cilostazol; Cost-Benefit Analysis; Decision Support Techniques; Humans; Intermittent Claudication; M	2014

cilostazol and Peripheral Arterial Diseases